U.S. FOOD & DRUG ADMINISTRATION

May 14, 2026

Cameron Ball, Ph.D.
Chief Technology Officer
Uh-Oh Labs Inc. dba Scout
3485 Victor Street
Santa Clara, CA 95054
**Re: Revocation of EUA210666**

Dear Dr. Ball:
This letter is in response to the request from Uh-Oh Labs Inc. (dba Scout), in a letter dated May 5, 2026, that the U.S. Food and Drug Administration (FDA) revoke the EUA for the UOL COVID-19 Test issued on February 8, 2022, and amended on March 25, 2022, August 2, 2022, September 9, 2022, November 8, 2022, July 6, 2023, and January 25, 2024. FDA understands that as of the date of this letter there are no viable UOL COVID-19 Test reagents remaining in distribution in the United States.

The authorization of a device for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3) may, pursuant to section 564(g)(2) of the Act, be revoked when circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the Act). Because Uh-Oh Labs Inc. (dba Scout) has requested that FDA revoke the EUA for UOL COVID-19 Test, FDA has determined that it is appropriate to protect the public health or safety to revoke this authorization. Accordingly, FDA hereby revokes EUA210666 for UOL COVID-19 Test, pursuant to section 564(g)(2)(C) of the Act. As of the date of this letter, the UOL COVID-19 Test is no longer authorized for emergency use by FDA.

Notice of this revocation will be published in the *Federal Register*, pursuant to section 564(h)(1) of the Act.

Sincerely,

_____
Ellen J. Flannery, J.D.
Deputy Center Director for Policy
Director, Office of Policy
Center for Devices and Radiological Health
Food and Drug Administration